Abstract
In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure established a definition of a new category of BP levels called ‘prehypertension’ (preHT) that included individuals with a systolic BP of 120–139 mm Hg or a diastolic BP of 80–89 mm Hg. Patients with preHT were considered to be at increased risk for progression to hypertension and in individuals with BP in the range 130/80 to 139/89 mmHg the risk of developing hypertension was twice as high as in subjects with lower values. Still then there has been a large debate whether the introduction of preHT was based on evidence and as a consequence, it was fully justified. It has been suggested that the term prehypertension may in many subjects create anxiety and a need for unnecessary medical visits and examinations. This group of patients is also very heterogeneous and it has been pointed out that subdividing preHT group into individuals with normal BP and high normal BP would much better correspond to the continuum of BP risk for CV disease. Finally, despite some data suggesting the potential benefits of antihypertensive therapy in patients with preHT (high normal BP), there are still no hard evidences on the outcome reduction by giving antihypertensive drugs in these individuals.
Keywords: Blood pressure, cardiovascular risk, high normal blood pressure, hypertension, prehypertension, risk stratification.
Current Vascular Pharmacology
Title:Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Volume: 12 Issue: 4
Author(s): Michalska Marta, Alberto Zanchetti, Nathan D. Wong, Jolanta Malyszko, Jacek Rysz and Maciej Banach
Affiliation:
Keywords: Blood pressure, cardiovascular risk, high normal blood pressure, hypertension, prehypertension, risk stratification.
Abstract: In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure established a definition of a new category of BP levels called ‘prehypertension’ (preHT) that included individuals with a systolic BP of 120–139 mm Hg or a diastolic BP of 80–89 mm Hg. Patients with preHT were considered to be at increased risk for progression to hypertension and in individuals with BP in the range 130/80 to 139/89 mmHg the risk of developing hypertension was twice as high as in subjects with lower values. Still then there has been a large debate whether the introduction of preHT was based on evidence and as a consequence, it was fully justified. It has been suggested that the term prehypertension may in many subjects create anxiety and a need for unnecessary medical visits and examinations. This group of patients is also very heterogeneous and it has been pointed out that subdividing preHT group into individuals with normal BP and high normal BP would much better correspond to the continuum of BP risk for CV disease. Finally, despite some data suggesting the potential benefits of antihypertensive therapy in patients with preHT (high normal BP), there are still no hard evidences on the outcome reduction by giving antihypertensive drugs in these individuals.
Export Options
About this article
Cite this article as:
Marta Michalska, Zanchetti Alberto, Wong D. Nathan, Malyszko Jolanta, Rysz Jacek and Banach Maciej, Patients with Prehypertension - Do we have Enough Evidence to Treat them?, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/15701611113119990126
DOI https://dx.doi.org/10.2174/15701611113119990126 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview
Current Clinical Pharmacology Effects of Blood Pressure Control in Cardiovascular Prevention
Current Pharmaceutical Design <i>Helicobacter Pylori</i> Interacts with Serum Vitamin D to Influence Hypertension
Current Aging Science Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Disease in Masked Hypertension: Clinical Implications
Current Hypertension Reviews The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews Effect of Soy Isoflavone Supplementation on Endothelial Dysfunction and Oxidative Stress in Equol-Producing Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets The Physiology and Pathophysiology of a Novel Angiotensin Receptor-binding Protein ATRAP/Agtrap
Current Pharmaceutical Design Is Hypertension an Inflammatory Process?
Current Pharmaceutical Design Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review
Current Neuropharmacology Bioavailability of Quercetin: Problems and Promises
Current Medicinal Chemistry Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews Management of the Metabolic Syndrome as a Strategy for Preventing the Macrovascular Complications of Type 2 Diabetes: Controversial Issues
Current Diabetes Reviews Ginseng for Treating Hypertension: A Systematic Review and Meta-Analysis of Double Blind, Randomized, Placebo-Controlled Trials
Current Vascular Pharmacology Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine Editorial [Hot Topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Hypertension-Related Disorders (Executive Guest Editor: Aurelio Leone)]
Current Pharmaceutical Design Lone Atrial Fibrillation- A Diagnosis of Exclusion
Current Pharmaceutical Design Analysis of the Salivary Microbiome in the Periodontal Disease Patients with Hypertension and Non-hypertension
Current Bioinformatics Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology